Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 788 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... January 15, 2024 5th Grader Follows His Gut By Calling 911 On School Bus... January 9, 2020 Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 Cancer in My Community: Encouraging Cancer Screening in Estonia May 23, 2023 Load more HOT NEWS Fructose Fuels Cancer Growth Indirectly, Lab Study Finds Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast... All in the Family – A Story about Genetics and Breast...
